drugset / Trial / NCT05638672
COVID-19 Huashi Baidu Formula Clinical Study
Unknown
300 enrolled
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Beijing YouAn Hospital · collabKamuzu University of Health Sciences · collabKossamak Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Combined with the regional and population characteristics of Asia and Africa, Huashi Baidu Granule was used to intervene in mild and moderate patients with COVID-19, evaluate its efficacy and safety, and clarify its characteristics of action.
Timeline
- Start
- 2023-05-06
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Huashibaidu granule | Traditional medicine (herbal / TCM) | 10 g | Oral |
| Comparator | Monapiravir | Unknown | 800 mg | — |